Karuna clears PhII hurdle in schizophrenia, takes aim at a pivotal in blockbuster hunt — shares soar
When Karuna went public last year, the biotech cited one small Eli Lilly study of their anti-psychotic xanomeline that delivered a whopping 24-point average improvement in schizophrenics’ PANSS score over placebo — far and above the average 9-10 point advantage cited for the average drug approved for use among these patients.
Now, after wrapping a big Phase II of a xanomeline combo with a sizable 182 patients, the margin on success has shrunk considerably, but the team $KRTX can still count on a solidly positive average outcome as well as — crucially — the safety profile they were looking for.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.